Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MIRASOL
2024-516111-25-00Phase 3Completed
- Sponsor
- ImmunoGen
- Start
- Oct 2024
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 12
01
Overview
Phase 3, randomised, open-label trial of mirvetuximab soravtansine in platinum-resistant epithelial ovarian cancer (PROC), primary peritoneal cancer (PPC) and fallopian tube cancer (PFTC) (2 arms), sponsored by ImmunoGen. Primary endpoint: Progression-free survival (PFS). Started Oct 2024; status: completed.
02
Drugs
mirvetuximab soravtansine
03
Conditions
platinum-resistant epithelial ovarian cancer (PROC)primary peritoneal cancer (PPC)fallopian tube cancer (PFTC)
Beyond the preview
Go deeper on 2024-516111-25-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-516111-25-00.